A Phase 2a, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Pf-06823859 In Adult Subjects With Dermatomyositis

Trial Profile

A Phase 2a, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Pf-06823859 In Adult Subjects With Dermatomyositis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs PF 6823859 (Primary)
  • Indications Dermatomyositis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 11 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 15 Jan 2018.
    • 07 Nov 2017 Planned initiation date changed from 20 Oct 2017 to 30 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top